Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1200 participants.

Also called NCT06645522

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
  • Yi Yang Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06645522
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06645522. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-30 (anticipated); primary completion 2026-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Edaravone dexborneol
Intervention (Drug)
Placebo
Lead sponsor
Yi Yang (class: other)

Record details

Record id
cardio:ct-nct06645522
Content hash
98d231e3ad174a1f96edc77266b342eab29ca47ec99c03840e631fab4ea023e6